Last reviewed · How we verify

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair — Portfolio Competitive Intelligence Brief

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair pipeline: 0 marketed, 0 filed, 0 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 5 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ALK-Abelló A/S · 1 shared drug class
  2. ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 1 shared drug class
  3. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  4. Astellas Pharma Global Development, Inc. · 1 shared drug class
  5. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  6. Cougar Biotechnology, Inc. · 1 shared drug class
  7. GU Research Network, LLC · 1 shared drug class
  8. Hoffmann-La Roche · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair:

Cite this brief

Drug Landscape (2026). Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/han-xu-m-d-ph-d-fapcr-sponsor-investigator-irb-chair. Accessed 2026-05-16.

Related